Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yeong Oh

Internal Medicine Glen Burnie, MD Medical Doctor

NPI 1215953914 CMS profile 100927

7927 Ritchie Hwy., Glen Burnie, MD 21061

Open in the dashboard

General payments

$1,621

93 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yeong Oh of Glen Burnie, MD is reported in the CMS Open Payments database as having received $1,621 across 93 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19 1
2024 General $46 1
2023 General $96 1
2022 General $60 3
2021 General $18 1
2020 General $229 15
2019 General $1,153 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yeong Oh
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Yeong Oh were reported at $19. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Yeong Oh Internal Medicine median Middle half National median
2019 $1,153 $159 $48–$570 $163
2020 $229 $119 $33–$402 $114
2021 $18 $135 $37–$521 $132
2022 $60 $141 $42–$496 $149
2023 $96 $149 $45–$519 $160
2024 $46 $154 $47–$537 $164
2025 $19 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $289 12 payments
  2. Pfizer Inc. $166 12 payments
  3. Lilly USA, LLC $164 12 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $149 11 payments
  5. Gilead Sciences, Inc. $125 1 payment
  6. Amarin Pharma Inc. $124 8 payments
  7. Novartis Pharmaceuticals Corporation $108 7 payments
  8. GlaxoSmithKline, LLC. $90 5 payments
  9. Janssen Pharmaceuticals, Inc $68 4 payments
  10. ACADIA Pharmaceuticals Inc $57 4 payments
  11. Other $281 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,621 93 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $262 10 payments
  2. TRULICITY $130 9 payments
  3. Epclusa $125 1 payment
  4. JARDIANCE Diabetes $101 7 payments
  5. BASAGLAR $101 7 payments
  6. JARDIANCE Diabetes $92 6 payments
  7. Vascepa $91 6 payments
  8. ENTRESTO $89 6 payments
  9. CHANTIX $84 6 payments
  10. SPIRIVA RESPIMAT $84 7 payments
  11. Other $1,149 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 161 drugs

Part D claims

14,372

Median for Internal Medicine: 777

Drug cost

$1,399,015

Median for Internal Medicine: $73,373

Branded share of claims

24.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 233 $236,894
Trulicity Dulaglutide Brand 131 $165,444
Eliquis Apixaban Brand 111 $110,876
Farxiga Dapagliflozin Propanediol Brand 134 $102,269
Tradjenta Linagliptin Brand 152 $92,951
Myrbetriq Mirabegron Brand 129 $69,052
Januvia Sitagliptin Phosphate Brand 76 $58,785
Ozempic Semaglutide Brand 43 $49,758
Linzess Linaclotide Brand 83 $48,550
Rybelsus Semaglutide Brand 22 $38,087

The 10 drugs with the highest cost, of 161 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$326,203

Of which drugs: $19,186

Medicare patients

666

Average age 78

Services billed

8,247

398 women, 268 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 35%
Arthritis 32%
Osteoporosis 31%
Depression 25%
Chronic kidney disease 24%
Ischemic heart disease 23%
Atrial fibrillation 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 225 225 $18,410
Injection, methylprednisolone acetate, 1 mg J1010 Office 48 2,845 $292
Injection, methylprednisolone acetate, 40 mg J1030 Office 14 17 $55

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

93 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record